ACM
NVO

Atika Capital Management’s Novo Nordisk NVO Stock Holding History

Atika Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$4.3M – 88
2024
Q4 		$4.3M Buy
+500
New +$54.1K 0.46% 72

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Atika Capital Management's NVO Position: Q3 2024 in Review

Atika Capital Management sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 68,000 shares — an estimated $9.71M sold.

Atika Capital Management first reported a position in NVO in Q4 2022 and held it in 4 quarters. The position peaked at $12.9M in Q1 2024. 1,785 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Atika Capital Management reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • Atika Capital Management sold 68,000 Novo Nordisk shares in Q3 2024, an estimated $9.71M.
  • Atika Capital Management first reported a position in Novo Nordisk in Q4 2022 and held it in 4 quarters.
  • Atika Capital Management's Novo Nordisk position peaked at $12.9M in Q1 2024.
  • 1,785 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Atika Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.